Navigation Links
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Date:7/12/2011

 Studies suggest that blockade of IL-6 signaling, one of several key cytokines involved in the inflammatory processes related to RA, may reduce inflammation of the joints, prevent long-term damage and relieve certain systemic effects of RA such as decreased hemoglobin, fatigue and osteoporosis.

About the ALIGN TrialThe 300-patient ALIGN trial is a randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of sarilumab in patients with AS who had an inadequate response to NSAIDs.  The primary outcome measure of the trial was the percentage of patients who achieved a 20% improvement in AS International Working Group Criteria for improvement (ASAS20) at 12 weeks.  The secondary endpoints included ASAS40 response, partial remission, and changes in disease activity, safety and tolerability.  In the ALIGN trial, the same dose regimens were tested as in part A of the MOBILITY trial.  Further details about the ALIGN trial can be found at http://clinicaltrials.gov/ct2/results?term=SAR153191+align.

About SanofiSanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.  Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase III clinical
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
2. Sanofi Enters Into Research Collaboration with Weill Cornell Medical College to Discover New Treatments for Tuberculosis
3. Sanofi Pasteur Commends Winners of International BioGENEius Challenge
4. Sanofi Announces Positive Results from the "All to Target" Study Evaluating Two Lantus® and Apidra® Regimens Versus Premixed Regimen
5. Medco, United BioSource and Sanofi Signed Global Agreement to Improve Quality of Patient Care Through Real-World Evidence
6. Sanofi Enters Into Research Collaboration With Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss
7. Sanofi Pasteur Donates Tdap Vaccine to Aid Storm Victims
8. sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
9. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
10. Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research
11. Sanofi-Aventis Completes Acquisition of Genzyme Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)... MOUNTAIN VIEW, Calif. , July 24, 2014 /PRNewswire/ ... that it will release its second quarter 2014 financial ... 31, 2014. In conjunction with the release, the ... community at 5:00 p.m. Eastern Time on ... results of the quarter and other business developments. ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the Wedbush Life Sciences Conference in New York on ... Interested parties may access a live audio webcast of the ... www.BMRN.com .  A replay of the call will be ...
... Merck,s Schering-Plough unit current and former pharmaceutical representatives ... opinion issued by a Federal Court in Connecticut. ... The law firms of Joseph, Herzfeld, Hester ... represent the plaintiffs in a Nationwide Collective Law Suit. ...
Cached Medicine Technology:BioMarin to Present at the Wedbush Life Sciences Conference 2UPDATE: Total Victory for Schering-Plough (Now Merck) Pharmaceutical Reps in National Suit for Overtime Pay 2
(Date:7/24/2014)... July 25, 2014 Voted one of ... the global clients, BellasDress focuses on providing its new ... fashion information. Recently, the company has announced its new ... the new range is created according to the latest ... discounts, up to 68% off. , As a matter ...
(Date:7/24/2014)... 2014 The report, “Content Delivery ... market into various sub-segments with an in-depth analysis ... drivers and restraints for this market with insights ... market data tables and 36 figures spread through ... Networks (CDN) Market” at http://www.marketsandmarkets.com/Market-Reports/content-delivery-networks-cdn-market-657.html . ...
(Date:7/24/2014)... Just as fitness and health professionals ... own financial and marketing strength to be important as ... the next level by using the most powerful communication ... Broadcast, Call Tracking and SMS texting solutions . ... messages are quickly become integral in marketing and communication ...
(Date:7/24/2014)... its 2014 Power of A Award winners, including two ... , The ASA Global Humanitarian Outreach (GHO) program ... the top honors from ASAE. GHO was honored for ... on the global anesthesia crisis and supporting low income ... honored with a Power of A Silver Award for ...
(Date:7/24/2014)... appears to increase the risk for head and neck cancer ... with DM, but the risk of HNC in patients with ... cancer is the sixth most common type of cancer. It ... an estimated 650,000 new cancer cases and 350,000 cancer deaths ... Insurance Research Database to examine the risk of HNC in ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 2Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 3Health News:CDN Market by Delivery Technologies & Solutions Expected to Reach $12.16 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3
... sites nationwide, - Triples network bandwidth to more than 1 Gbps at ... ... solution, ROCHESTER, N.Y., March 18 Time Warner Telecom,Inc. (Nasdaq: ... businesses, today announced a multi-year, contract,to deploy an eight-site IP VPN solution ...
... PartsSource, the nation,s,leading supplier of replacement medical repair ... Team NEO award. Team NEO recognizes,the exceptional companies ... as the engines fueling the Cleveland area economy., ... what,s right about Northern Ohio,business," said President & ...
... Using data from the SCIAMACHY instrument aboard ESA,s Envisat ... regionally elevated atmospheric carbon dioxide the most important ... from manmade emissions. , More than 30 billion tonnes ... into the atmosphere annually by human activities, mainly through ...
... New U of T research holds promise for ... serve as a model for future therapies against the ... Stagljar, University of Toronto scientists have identified several compounds ... ExoS). One of these compounds, exosin, significantly inhibited infections ...
... March 18 On The Go,Healthcare, Inc. (OTC ... computer hardware, software and systems integrator,announced today that ... the Company has sold its Value Added Reseller ... (OTC Bulletin Board: FLIP). The,terms of the sale, ...
... or not relatives talk about the familys history of ... and testing for those at moderate risk of developing ... today at the American Society for Preventive Oncology meeting ... African Americans participate less often in genetic counseling and ...
Cached Medicine News:Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 2Health News:CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecom's IP VPN 3Health News:Envisat makes first ever observation of regionally elevated CO2 from manmade emissions 2Health News:Envisat makes first ever observation of regionally elevated CO2 from manmade emissions 3Health News:Research promising for cystic fibrosis 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 4Health News:Family communication impacts attitude about genetic counseling/testing for breast cancer 2
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures....
... Webster is the source for a complete ... catheters for left-sided mapping - all with ... come to expect from the leader in ... sinus diagnostic catheters are specifically designed and ...
... Inquiry 5FR Soft HIS diagnostic ... a uniquely designed curve that ... in the HIS bundle. In ... designed to reduce the risk ...
Standard Deflectable Catheters...
Medicine Products: